Reverse Genetic System for Rift Valley Fever Virus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack an effective reverse genetic system for Rift Valley fever virus (RVFV) to develop vaccines, screen antivirals, and create markers, particularly for the Phlebovirus genus, which is recalcitrant due to poor understanding of molecular virology and replication strategies.
Innovation Solution
A reverse genetic system comprising anti-viral sense RNA expression plasmids, either alone or combined with viral structural protein expression plasmids, is developed to generate infectious clones and recombinant viruses, allowing for the evaluation of gene function, vaccine development, and antiviral screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If reverse genetic system is developed for Phlebovirus, then vaccine development and antiviral screening capability is improved, but device complexity and system construction difficulty increases
Solution Approach 1:
The Phlebovirus genome is divided into three separate cDNA segments (S, M, and L segments) that are cloned into individual expression plasmids. Each plasmid contains a specific viral RNA segment under the control of a T7 promoter, allowing independent manipulation and expression. This segmentation enables systematic study of viral genes and facilitates vaccine development while managing system complexity through modular construction.
Solution Approach 2:
A T7 RNA polymerase expression plasmid is introduced as an intermediary component to drive transcription of the viral cDNA segments. The T7 polymerase system serves as a controlled mediator that enables efficient in vitro transcription of the cloned viral segments, which are then transfectioned into host cells to generate infectious viral particles. This intermediary system provides a reliable and controllable method for viral genome expression.
2Loss of information
If infectious clones are generated using reverse genetics, then gene function evaluation capability is improved, but time and resources required for virus recovery increases
Solution Approach 1:
The viral cDNA segments are pre-cloned into expression plasmids with appropriate promoters and regulatory elements before transfection. The T7 RNA polymerase system is pre-established in the host cells or co-transfected, enabling immediate transcription upon plasmid introduction. This preliminary preparation of the genetic system accelerates the virus recovery process by eliminating the need for gradual system assembly and allows direct evaluation of gene function through targeted mutagenesis and complementation assays.
3Productivity
If recombinant viruses are produced through plasmid transfection, then vaccine development efficiency is improved, but manufacturing precision and viral titer control becomes more difficult
Solution Approach 1:
The system enables control of viral production parameters through plasmid DNA concentration, transfection efficiency optimization, and host cell state regulation. By adjusting the ratio and amount of co-transfected plasmids (viral cDNA segments and T7 polymerase plasmid), researchers can control the transcription efficiency and resulting viral titer. This parameter control allows optimization of vaccine production while maintaining sufficient precision for experimental and manufacturing requirements.
Data Source
AI summary
The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses.